MY176987A - 2-substituted cephem compounds - Google Patents

2-substituted cephem compounds

Info

Publication number
MY176987A
MY176987A MYPI2015701345A MYPI2015701345A MY176987A MY 176987 A MY176987 A MY 176987A MY PI2015701345 A MYPI2015701345 A MY PI2015701345A MY PI2015701345 A MYPI2015701345 A MY PI2015701345A MY 176987 A MY176987 A MY 176987A
Authority
MY
Malaysia
Prior art keywords
cephem compounds
compounds
substituted cephem
substituted
pharmaceutical compositions
Prior art date
Application number
MYPI2015701345A
Inventor
Xiangmin Liao
Neil David Pearson
Israil Pendrak
Reema Thalgi
Kenji Yamawaki
Katsuki Yokoo
Jun Sato
Hiroki Kusano
Toshiaki Aoki
Original Assignee
Glaxo Group Ltd
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49955387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY176987(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, Shionogi & Co filed Critical Glaxo Group Ltd
Publication of MY176987A publication Critical patent/MY176987A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/48—Methylene radicals, substituted by hetero rings
    • C07D501/50—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by an aliphatic carboxylic acid, which is substituted by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The compounds of the subject invention are related to 2-substituted cephem compounds, which have a wide antimicrobial spectrum, in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical compositions comprising the same.
MYPI2015701345A 2012-10-29 2013-10-29 2-substituted cephem compounds MY176987A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261719523P 2012-10-29 2012-10-29
PCT/IB2013/002423 WO2014068388A1 (en) 2012-10-29 2013-10-29 2 substituted cephem compounds

Publications (1)

Publication Number Publication Date
MY176987A true MY176987A (en) 2020-08-31

Family

ID=49955387

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015701345A MY176987A (en) 2012-10-29 2013-10-29 2-substituted cephem compounds

Country Status (38)

Country Link
US (2) US20150299223A1 (en)
EP (1) EP2917223B1 (en)
JP (1) JP6316830B2 (en)
KR (1) KR20150081428A (en)
CN (2) CN107652310A (en)
AR (1) AR093261A1 (en)
AU (2) AU2013340469B2 (en)
BR (2) BR112015009460A2 (en)
CA (1) CA2889746A1 (en)
CL (1) CL2015001084A1 (en)
CR (1) CR20150224A (en)
CY (1) CY1121721T1 (en)
DK (1) DK2917223T3 (en)
EA (1) EA031881B1 (en)
ES (1) ES2717923T3 (en)
HK (1) HK1214826A1 (en)
HR (1) HRP20190603T1 (en)
HU (1) HUE042664T2 (en)
IL (1) IL238149A (en)
LT (1) LT2917223T (en)
MA (1) MA38039A1 (en)
ME (1) ME03359B (en)
MX (1) MX365534B (en)
MY (1) MY176987A (en)
NZ (1) NZ628527A (en)
PE (1) PE20151204A1 (en)
PH (2) PH12015500914A1 (en)
PL (1) PL2917223T3 (en)
PT (1) PT2917223T (en)
RS (1) RS58611B1 (en)
SG (2) SG11201502540RA (en)
SI (1) SI2917223T1 (en)
TR (1) TR201904001T4 (en)
TW (1) TWI625333B (en)
UA (1) UA117666C2 (en)
UY (1) UY35103A (en)
WO (1) WO2014068388A1 (en)
ZA (1) ZA201502174B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912040A4 (en) * 2012-10-29 2016-06-01 Shionogi & Co Processes for production of intermediates for 2-alkyl cephem compounds
WO2014104148A1 (en) * 2012-12-26 2014-07-03 塩野義製薬株式会社 Cephem compound
JP6377570B2 (en) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Pharmaceutical composition containing 2-substituted cephem compound
CN106795176B (en) 2014-09-04 2020-11-10 盐野义制药株式会社 Salt of cephalosporin derivative, crystalline solid thereof and process for producing the same
JP6814730B2 (en) 2014-09-05 2021-01-20 ジェネンテック， インコーポレイテッド Therapeutic compounds and their use
EP3189049B1 (en) 2014-09-05 2024-03-20 Genentech, Inc. Phthalazine derivatives of formula (i) as pcaf and gcn5 inhibitors for use in the treatment of cancer
CN104529735A (en) * 2014-12-08 2015-04-22 苏州施亚生物科技有限公司 1-(5-bromo-4-chloro-2-fluorophenyl)-ethanone synthesis method
JP6659703B2 (en) 2015-01-09 2020-03-04 ジェネンテック， インコーポレイテッド Pyridazinone derivatives and their use in the treatment of cancer
JP2018521021A (en) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ Efflux pump inhibitors and their therapeutic use
CA2988405A1 (en) * 2015-06-11 2016-12-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P62-zz chemical inhibitor
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
BR112018009725A8 (en) * 2015-12-10 2019-02-26 Naeja Rgm Pharmaceuticals Ulc cefém compounds, their production and use
CN110612119A (en) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
EP3589295A4 (en) 2017-02-28 2020-11-04 Endocyte, Inc. Compositions and methods for car t cell therapy
CN106966914B (en) * 2017-05-04 2019-02-22 无锡捷化医药科技有限公司 A kind of preparation method of the chloro- 2- aminoacetophenone of the bromo- 4- of 5-
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN108892639B (en) * 2018-08-13 2021-05-14 云南民族大学 Efficient and environment-friendly method for preparing quinolone compounds
CN113024582A (en) * 2020-03-04 2021-06-25 刀鹏 Synthesis method of cefepime hydrochloride
CN116528874A (en) * 2021-01-12 2023-08-01 上海森辉医药有限公司 Cefprozil antibacterial compound and preparation method thereof
CN113698365A (en) * 2021-08-30 2021-11-26 成都大学 Preparation method of cefditoren side chain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487079A (en) * 1966-01-14 1969-12-30 Bristol Myers Co Certain alpha-amino bicyclic beta-lactam carboxylic acids
US3926983A (en) * 1974-08-30 1975-12-16 Squibb & Sons Inc 3-Heterothio{8 (alkoxycarbonyl)thioacetyl{9 cephalosporanic derivatives
JPS5511600A (en) * 1978-07-10 1980-01-26 Fujisawa Pharmaceut Co Ltd Cephem compound, its salt, their preparation and remedy and prophylactic for microbism containing mainly the same
US4268509A (en) 1978-07-10 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds and processes for preparation thereof
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
GB8816519D0 (en) 1987-07-23 1988-08-17 Ici Plc Antibiotic compounds
JPH0228185A (en) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd Cephalosporin compound and synthetic intermediate thereof
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5095012A (en) * 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
DE69431691T2 (en) 1993-04-16 2003-08-21 Basilea Pharmaceutica Ag Binni Cephalosporin derivatives
EP0838465A1 (en) 1996-10-22 1998-04-29 F. Hoffmann-La Roche Ag Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics
DK0841339T3 (en) 1996-11-06 2007-07-02 Basilea Pharmaceutica Ag Vinylpyrrolidinone-cephalosporin derivatives
JP2003078440A (en) 2001-08-30 2003-03-14 Kyocera Corp High frequency switch circuit
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
JP4557859B2 (en) 2005-09-29 2010-10-06 富士通株式会社 Frequency division multiplexing transmission / reception apparatus and transmission / reception method
EP1994035A1 (en) 2006-03-16 2008-11-26 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
NZ591728A (en) * 2008-10-31 2012-12-21 Shionogi & Co Cephalosporin having catechol group
US8883773B2 (en) * 2010-04-05 2014-11-11 Shionogi & Co., Ltd. Cephem compound having pseudo-catechol group
CA2795322A1 (en) * 2010-04-05 2011-10-13 Shionogi & Co., Ltd. Cephem compound having catechol group
US9085589B2 (en) * 2010-04-28 2015-07-21 Shionogi & Co., Ltd. Cephem derivative
WO2012044561A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
JP6006201B2 (en) * 2011-04-28 2016-10-12 塩野義製薬株式会社 Novel cephem compounds having catechol or pseudo-catechol structure
JPWO2013002215A1 (en) * 2011-06-27 2015-02-23 塩野義製薬株式会社 Cephem compound having pyridinium group
TWI547496B (en) * 2011-10-04 2016-09-01 葛蘭素集團公司 Antibacterial compounds
JPWO2013051597A1 (en) * 2011-10-04 2015-03-30 塩野義製薬株式会社 Cephem derivatives with catechol groups
EP2912040A4 (en) 2012-10-29 2016-06-01 Shionogi & Co Processes for production of intermediates for 2-alkyl cephem compounds

Also Published As

Publication number Publication date
LT2917223T (en) 2019-04-10
ZA201502174B (en) 2016-01-27
UY35103A (en) 2014-05-30
HRP20190603T1 (en) 2019-05-31
ME03359B (en) 2019-10-20
TR201904001T4 (en) 2019-04-22
BR122016025225A2 (en) 2019-07-30
CR20150224A (en) 2015-10-19
PL2917223T3 (en) 2019-06-28
RS58611B1 (en) 2019-05-31
PH12015500914B1 (en) 2015-06-29
CA2889746A1 (en) 2014-05-08
EP2917223A1 (en) 2015-09-16
MX365534B (en) 2019-06-06
AR093261A1 (en) 2015-05-27
HK1214826A1 (en) 2016-08-05
CN104884460A (en) 2015-09-02
PH12017500755A1 (en) 2018-01-29
AU2017200717A1 (en) 2017-02-23
JP6316830B2 (en) 2018-04-25
PE20151204A1 (en) 2015-09-03
EP2917223B1 (en) 2019-01-16
BR112015009460A2 (en) 2017-07-04
EA031881B1 (en) 2019-03-29
CL2015001084A1 (en) 2015-08-28
IL238149A (en) 2017-09-28
UA117666C2 (en) 2018-09-10
PT2917223T (en) 2019-05-17
MA38039A1 (en) 2016-05-31
EA201590844A1 (en) 2015-09-30
AU2013340469B2 (en) 2016-11-03
TW201431863A (en) 2014-08-16
CY1121721T1 (en) 2020-07-31
US20170281532A1 (en) 2017-10-05
CN107652310A (en) 2018-02-02
MX2015005429A (en) 2015-07-21
ES2717923T3 (en) 2019-06-26
DK2917223T3 (en) 2019-04-15
NZ628527A (en) 2017-03-31
US10174053B2 (en) 2019-01-08
WO2014068388A1 (en) 2014-05-08
PH12015500914A1 (en) 2015-06-29
JP2015534995A (en) 2015-12-07
AU2013340469A1 (en) 2015-04-16
KR20150081428A (en) 2015-07-14
TWI625333B (en) 2018-06-01
SG10201703589TA (en) 2017-06-29
HUE042664T2 (en) 2019-07-29
CN104884460B (en) 2017-11-03
US20150299223A1 (en) 2015-10-22
SI2917223T1 (en) 2019-05-31
SG11201502540RA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
PH12017500755A1 (en) 2 substituted cephem compounds
PH12014501671B1 (en) Amidine substituted beta-lactam compounds, their preparation and use as antibacterial agents
PH12015501440B1 (en) Zinc-lysine complex
MX2014011825A (en) Isoxazole î²-lactamase inhibitors.
MX2014011827A (en) 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE ß-LACTAMASE INHIBITORS.
EP2780447A4 (en) Novel isolated bacteriophage having e. coli-specific bactericidal activity and antibacterial composition comprising the same
MX2014014832A (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.
IN2015DN00598A (en)
TN2015000262A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
MX2017007371A (en) Antibacterial compounds having broad spectrum of activity.
IN2014DN10449A (en)
MX2014015345A (en) Pyranopyridone inhibitors of tankyrase.
WO2014105777A8 (en) Cobicostat dichlohydrate salt
MX2015015251A (en) Quinolone derivatives.
WO2015044434A3 (en) Fluor-9-methyl-β-carbolines
PH12015501428A1 (en) Antibacterial compounds
EP2866569B8 (en) Antimicrobial composition
PT2802558T (en) Compounds having antibacterial activity, process for their preparation and pharmaceutical compositions comprising them
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
WO2014101294A9 (en) Glycopeptide compound or pharmaceutical salt thereof and method for preparing same, and pharmaceutical compositions and applications thereof
UA74648U (en) 1,2,4-triazole derivatives exhibiting antimicrobial activity
WO2014006601A3 (en) Nanoparticle compositions of antibacterial compounds and other uses thereof
UA105703C2 (en) 7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzdiazepin-2-ones as analgetic agents
AU2012905670A0 (en) Improved antimicrobial composition
AU2012905697A0 (en) Improved antimicrobial composition